B · Normal
[Forui Medical: The core product of the joint-stock company has obtained the De Novo marketing authorization from the US FDA] On November 6, Forui Medical (300049.SZ) announced that the core product SONOVEIN® of the company's joint-stock company Terraclon of France obtained the marketing authorization granted by the US FDA through the DeNovo channel on November 4, 2026, becoming the first and only non-invasive high-intensity focused ultrasound platform approved for the treatment of varicose veins in the United States. The company holds 27.70% of the shares of Terraclion. This approval will not change the shareholding ratio and the scope of the consolidated statements, nor will it directly generate revenue.
Comments